PHARMA - Relationships

Relationships Table

Entities - Color - Target Drug Disease Lo Med Hi
Brain Cancer 1,542 Disease Target Kallikrein-8 19 1 0.01 -0.97 0.05 0.68
Infection 766,637 Disease Target Eotaxin-2/CCL24 19 2 0.00 -0.95 0.11 0.55
Poisoning 53,779 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.59
Carcinoma 433,099 Disease Target Kallikrein-8 19 2 0.00 -0.95 0.11 0.56
Tissue-Type Plasminogen Activator 5,020 Target Target Kallikrein-8 19 1 0.00 -0.97 0.05 0.64
Depression 220,092 Disease Target Mu-Type Opioid Receptor 19 1 0.00 -0.97 0.05 0.56
Cancer 1,053,491 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.53
Renal Failure 73,993 Disease Target 464.1 19 1 0.00 -0.97 0.05 0.58
Osteoporosis 46,215 Disease Target ALK Phos 19 2 0.00 -0.95 0.11 0.61
Diabetes 332,602 Disease Target 464.1 19 1 0.00 -0.97 0.05 0.55
Diabetes 332,602 Disease Drug Kaad-Cyclopamine 19 1 0.00 -0.97 0.05 0.55
CCL2 3,560 Target Target Eotaxin-2/CCL24 19 2 0.01 -0.95 0.11 0.67
Prostate Cancer 71,064 Disease Target Kallikrein-8 19 1 0.00 -0.97 0.05 0.58
CD4 112,219 Target Target Eotaxin-2/CCL24 19 2 0.00 -0.95 0.11 0.59
Metastatic Breast Cancer 9,288 Disease Drug Aralen (Chloroquine)- FDA 19 1 0.00 -0.97 0.05 0.63
Headache 50,687 Disease Drug Amitiza (Lubiprostone)- FDA 19 2 0.00 -0.95 0.11 0.60
CD68 6,424 Target Target AMAC-1 19 1 0.00 -0.97 0.05 0.64
Diarrhea 51,986 Disease Drug Amitiza (Lubiprostone)- FDA 19 7 0.01 -0.79 0.37 0.63
Cancer 1,053,491 Disease Target 464.1 19 2 0.00 -0.95 0.11 0.54
Non Small Cell Lung Cancer 28,563 Disease Target Kallikrein-8 19 1 0.00 -0.97 0.05 0.60
Lung Cancer 91,416 Disease Target Kallikrein-8 19 1 0.00 -0.97 0.05 0.58
744.1 22 Target Target 464.1 19 1 0.05 -0.95 0.05 0.83
Arthritis 128,324 Disease Target Eotaxin-2/CCL24 19 1 0.00 -0.97 0.05 0.57
Chronic Pain 21,087 Disease Target Mu-Type Opioid Receptor 19 1 0.00 -0.97 0.05 0.61
CD4 112,219 Target Target Tegument Protein Vp16 19 3 0.00 -0.92 0.16 0.60
Osteoarthritis 36,287 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.60
Tuberculosis 146,217 Disease Target Eotaxin-2/CCL24 19 1 0.00 -0.97 0.05 0.57
Prostate Cancer 71,064 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.58
Renal Failure 73,993 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.58
Osteoarthritis 36,287 Disease Target Kallikrein-8 19 1 0.00 -0.97 0.05 0.60
Eotaxin 2,457 Target Target Eotaxin-2/CCL24 19 19 0.09 -0.22 1.00 0.76
Diabetes 332,602 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.55
Androgen Receptor 12,918 Target Drug Kaad-Cyclopamine 19 1 0.00 -0.97 0.05 0.62
Cancer 1,053,491 Disease Drug Amitiza (Lubiprostone)- FDA 19 1 0.00 -0.97 0.05 0.53
Ovarian Cancer 33,996 Disease Target Kallikrein-8 19 6 0.01 -0.83 0.32 0.64
Nausea 42,627 Disease Drug Amitiza (Lubiprostone)- FDA 19 6 0.01 -0.83 0.32 0.64
Prostate Cancer 71,064 Disease Target 464.1 19 1 0.00 -0.97 0.05 0.58
CCL7 274 Target Target Eotaxin-2/CCL24 19 1 0.01 -0.97 0.05 0.73
Dyspnea 24,781 Disease Drug Amitiza (Lubiprostone)- FDA 19 1 0.00 -0.97 0.05 0.60
Eotaxin-3/CCL26 26 Target Target Eotaxin-2/CCL24 19 10 0.45 -0.54 0.53 0.94
Skin Disease 6,955 Disease Target Eotaxin-2/CCL24 19 1 0.00 -0.97 0.05 0.64
Lung Cancer 91,416 Disease Drug Kaad-Cyclopamine 19 1 0.00 -0.97 0.05 0.58
Acute Promyelocytic Leukemia 4,780 Disease Target 464.1 19 1 0.00 -0.97 0.05 0.65
CD4 112,219 Target Target AMAC-1 19 1 0.00 -0.97 0.05 0.57
Colon Cancer 30,064 Disease Target Complement Decay-Accelerating Factor 19 1 0.00 -0.97 0.05 0.60
CD4 112,219 Target Target Complement Decay-Accelerating Factor 19 1 0.00 -0.97 0.05 0.57
Arthritis 128,324 Disease Target Kallikrein-8 19 1 0.00 -0.97 0.05 0.57
Mu Opioid Receptor 4,576 Target Target Mu-Type Opioid Receptor 19 5 0.02 -0.86 0.26 0.69
Cathepsin G 1,613 Target Target Kallikrein-8 19 1 0.01 -0.97 0.05 0.68
Pneumonia 81,521 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.58